Evidence map›Paper›PMID 42888267›Full record

ArticleNature chemical biology2026

Tryptoline stereoprobe elaboration identifies inhibitors of the GRPEL1-HSPA9 complex.

Rachel E Hayward, Raymond F Berkeley, Zijian Gao, Maximilian Garhammer, Marc A Morizono, Evert Njomen, Haoxin Li, Kristen E DeMeester, Victor Cociorva, Mark A Herzik and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rachel E Hayward *Department of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1080-8244
Raymond F Berkeley *Department of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3567-1547
Zijian GaoDepartment of Chemistry, University of Oxford, Oxford, UK.
Maximilian GarhammerDepartment of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany.
Marc A MorizonoDepartment of Biochemistry and Molecular Biophysics, University of California, San Diego, La Jolla, CA, USA.
Evert NjomenDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3508-2638
Haoxin LiDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Kristen E DeMeesterDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Victor CociorvaDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID http://orcid.org/0009-0002-7783-345X
Mark A HerzikDepartment of Biochemistry and Molecular Biophysics, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6653-6682
F Ulrich HartlDepartment of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID http://orcid.org/0000-0002-7941-135X
Bruno MelilloDepartment of Chemistry, Scripps Research, La Jolla, CA, USA. bmelillo@scripps.edu.ORCID http://orcid.org/0000-0002-9708-5287
Benjamin F CravattDepartment of Chemistry, Scripps Research, La Jolla, CA, USA. cravatt@scripps.edu.ORCID http://orcid.org/0000-0001-5330-3492

Funding

Chemical Proteomic Platforms for Radically Expanding Cancer DruggabilityR35CA231991 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2018 to 2026
$9.5M
Howard Hughes Medical Institute (HHMI) GT15176U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K99/R00 CA290143U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R35 CA231991U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35-GM138206U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32-GM008326
6 · The paper itself

Abstract

Activity-based protein profiling has identified hundreds of human proteins from diverse classes that react at cysteine residues with stereochemically defined electrophilic compounds (stereoprobes). The structure-activity relationships underlying these stereoprobe-protein interactions, however, remain poorly understood. Here, we show that the protein interaction landscape of tryptoline acrylamide stereoprobes can be profoundly altered by structural modifications distal to the acrylamide reactive group. Most stereoprobe liganding events occurred at nonorthosteric sites and evaded assignment by the machine learning-based cofolding model Boltz-2, which instead tended to misplace stereoprobes in orthosteric pockets (an outcome we term 'orthostery burnout'). We found that stereoprobes reacting with C124 in the nucleotide exchange factor GRPEL1 disrupt interactions with the mitochondrial HSP70 chaperone HSPA9/mortalin, leading to impairments in mitochondrial protein import and mitophagy induction. Our results highlight tryptoline acrylamides as a versatile source of covalent ligands targeting nonorthosteric sites on proteins, including tool compounds that perturb the mitochondrial HSP70 chaperone system.

Identifiers

PMID42888267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.